NO20084928L - Farmasoytiske sammensetninger - Google Patents

Farmasoytiske sammensetninger

Info

Publication number
NO20084928L
NO20084928L NO20084928A NO20084928A NO20084928L NO 20084928 L NO20084928 L NO 20084928L NO 20084928 A NO20084928 A NO 20084928A NO 20084928 A NO20084928 A NO 20084928A NO 20084928 L NO20084928 L NO 20084928L
Authority
NO
Norway
Prior art keywords
formulas
compounds
pharmaceutical compositions
lipid kinases
disorders
Prior art date
Application number
NO20084928A
Other languages
English (en)
Norwegian (no)
Inventor
Janet Gunzner
Georgette Castanedo
Alan Olivero
Richard Goldsmith
Tim Heffron
Simon Mathieu
Daniel P Sutherlin
Bing-Yan Zhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20084928L publication Critical patent/NO20084928L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20084928A 2006-04-26 2008-11-25 Farmasoytiske sammensetninger NO20084928L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79504806P 2006-04-26 2006-04-26
PCT/US2007/009866 WO2007127175A2 (en) 2006-04-26 2007-04-24 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
NO20084928L true NO20084928L (no) 2009-01-26

Family

ID=38606432

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084928A NO20084928L (no) 2006-04-26 2008-11-25 Farmasoytiske sammensetninger

Country Status (23)

Country Link
US (2) US8802670B2 (zh)
EP (2) EP2041139B1 (zh)
JP (1) JP5546240B2 (zh)
KR (1) KR101422301B1 (zh)
CN (1) CN101479274B (zh)
AR (1) AR060633A1 (zh)
AT (1) ATE532788T1 (zh)
AU (1) AU2007243457B2 (zh)
BR (1) BRPI0710943A2 (zh)
CA (1) CA2650290C (zh)
CL (1) CL2007001167A1 (zh)
DK (1) DK2041139T3 (zh)
ES (1) ES2377358T3 (zh)
HK (1) HK1127356A1 (zh)
IL (1) IL194762A (zh)
MX (1) MX2008013584A (zh)
NO (1) NO20084928L (zh)
PL (1) PL2041139T3 (zh)
PT (1) PT2041139E (zh)
RU (1) RU2443706C2 (zh)
TW (1) TWI498332B (zh)
WO (1) WO2007127175A2 (zh)
ZA (1) ZA200809546B (zh)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2271958T3 (es) * 1996-09-04 2007-04-16 Intertrust Technologies Corp Sistemas, procedimientos y tecnicas fiables de soporte de infraestructuras para comercio electronico seguro, transacciones electronicas, control y automatizacion de procedimientos comerciales, informatica distribuida y gestion de derechos.
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
BRPI0710866A2 (pt) * 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
DK2041139T3 (da) 2006-04-26 2012-01-16 Genentech Inc Farmaceutiske forbindelser
AR064154A1 (es) * 2006-12-07 2009-03-18 Piramed Ltd Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
RU2468027C2 (ru) 2006-12-07 2012-11-27 Ф. Хоффманн-Ля Рош Аг Ингибиторы фосфоинозитид-3-киназы и способы их применения
CN101679456B (zh) * 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5736171B2 (ja) * 2007-09-24 2015-06-17 ジェネンテック， インコーポレイテッド チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
ES2537624T3 (es) * 2007-10-26 2015-06-10 F. Hoffmann-La Roche Ag Derivados purina útiles como inhibidores de la quinasa PI3
GB0723748D0 (en) * 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
AR070865A1 (es) * 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2473549C2 (ru) * 2008-07-31 2013-01-27 Дженентек, Инк. Пиримидиновые соединения, композиции и способы применения
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8653098B2 (en) * 2008-11-20 2014-02-18 Genentech, Inc. Pyrazolopyridine PI3K inhibitor compounds and methods of use
ME02230B (me) 2009-01-08 2016-02-20 Curis Inc Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
CN102361878A (zh) 2009-03-24 2012-02-22 住友化学株式会社 用于制备硼酸酯化合物的方法
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
KR101792837B1 (ko) 2009-04-16 2017-11-02 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 키나아제 억제제로서 사용을 위한 이미다조피라진
CN102459272B (zh) * 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
CA2772371A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG176959A1 (en) * 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
WO2011005119A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
NZ598808A (en) * 2009-09-09 2014-07-25 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
CA2775942A1 (en) * 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
RU2515541C2 (ru) * 2009-11-12 2014-05-10 Ф.Хоффманн-Ля Рош Аг N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
WO2011101429A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
US8551981B2 (en) * 2010-10-08 2013-10-08 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
CN105859735B (zh) 2010-12-16 2018-03-09 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE INHIBITORS AS ANTIVIRAL AGENTS
CN103476767B (zh) 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
DK2691384T3 (en) 2011-03-28 2017-01-16 Mei Pharma Inc (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE
CN105461736B (zh) 2011-04-01 2018-06-12 柯瑞斯公司 具有锌结合位的磷脂酰肌醇3-激酶抑制剂
MX2014001063A (es) 2011-07-28 2014-09-01 Genentech Inc Modelo de cancer de mama animal no humano knock-in con h1047r de fosfoinositol 3-cinasa polipeptido catalitico alfa (pik3ca).
EP3048106B1 (en) 2011-11-23 2019-11-06 Cancer Research Technology Limited Thienopyrimidine as inhibitors of atypical protein kinase c
CN102643272B (zh) * 2011-12-30 2015-03-11 沈阳药科大学 新的噻吩并[3,2-d]嘧啶类化合物
CA2868392A1 (en) 2012-05-23 2013-11-28 Estelle DOUDEMENT Compositions and methods of obtaining and using endoderm and hepatocyte cells
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
IN2015MN00002A (zh) 2012-07-09 2015-10-16 Lupin Ltd
WO2014033196A1 (en) * 2012-08-30 2014-03-06 F. Hoffmann-La Roche Ag Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
CN104718212B (zh) 2012-10-10 2017-06-16 霍夫曼-拉罗奇有限公司 制备噻吩并嘧啶化合物的方法
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
HUE045192T2 (hu) * 2015-03-30 2019-12-30 Daiichi Sankyo Co Ltd 6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
EP3598134A1 (en) 2015-06-29 2020-01-22 F. Hoffmann-La Roche AG Methods of treatment with taselisib
KR20180086247A (ko) * 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
LT3458067T (lt) 2016-05-18 2021-04-26 Torqur Ag Neurologinių sutrikimų gydymas
EP3481399A4 (en) 2016-07-07 2020-04-01 Cardurion Pharmaceuticals, LLC METHOD FOR TREATING HEART INSUFFICIENCY
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
US20210147366A1 (en) 2018-04-06 2021-05-20 H. Lundbeck A/S Process for preparation of 2,2-dimethylpiperazine
BR112020021153A2 (pt) 2018-04-17 2021-03-23 Cardurion Pharmaceuticals, Llc sais de meglumina de tienopirimidinas
US20210346392A1 (en) * 2018-08-31 2021-11-11 Astellas Pharma Inc. Pharmaceutical composition for oral administration
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN111205310B (zh) * 2018-11-22 2023-12-19 上海迪诺医药科技有限公司 杂环稠合嘧啶衍生物、其药物组合物及应用
CN112920199B (zh) * 2020-06-02 2023-02-03 四川大学 一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物
US20240150358A1 (en) * 2020-06-03 2024-05-09 Kineta, Inc. Purines and methods of their use
CN113045582B (zh) * 2021-02-05 2022-12-23 中国药科大学 Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途
WO2023055181A1 (ko) * 2021-09-30 2023-04-06 한미약품 주식회사 PIKfyve 키나아제 억제제

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (zh) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Ｐｉ３キナーゼ阻害剤とその製造法
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
DE69943144D1 (de) * 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
CA2454976C (en) 2001-07-26 2011-05-10 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
WO2003034997A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
EP1444010A2 (en) 2001-10-30 2004-08-11 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
EA011807B1 (ru) 2002-07-10 2009-06-30 Лаборатуар Сероно Са Азолидинонвинильные производные конденсированного бензола
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US20050222225A1 (en) 2002-07-10 2005-10-06 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
WO2004017950A2 (en) * 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
RU2326881C9 (ru) * 2002-09-30 2009-04-10 Байер Фармасьютикалс Корпорейшн Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k)
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2007127183A1 (en) * 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
DK2041139T3 (da) 2006-04-26 2012-01-16 Genentech Inc Farmaceutiske forbindelser
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
CA2650303C (en) * 2006-04-26 2015-03-24 F. Hoffmann-La Roche Ag Thienopyrimidine pharmaceutical compounds and their use
RU2468027C2 (ru) * 2006-12-07 2012-11-27 Ф. Хоффманн-Ля Рош Аг Ингибиторы фосфоинозитид-3-киназы и способы их применения

Also Published As

Publication number Publication date
CA2650290C (en) 2015-11-17
DK2041139T3 (da) 2012-01-16
AR060633A1 (es) 2008-07-02
WO2007127175A2 (en) 2007-11-08
RU2443706C2 (ru) 2012-02-27
EP2041139A2 (en) 2009-04-01
ATE532788T1 (de) 2011-11-15
TW200813069A (en) 2008-03-16
CL2007001167A1 (es) 2008-01-25
PL2041139T3 (pl) 2012-05-31
BRPI0710943A2 (pt) 2012-06-26
US20160152632A9 (en) 2016-06-02
MX2008013584A (es) 2009-03-23
US20080076758A1 (en) 2008-03-27
US8802670B2 (en) 2014-08-12
RU2008145660A (ru) 2010-06-20
ES2377358T3 (es) 2012-03-26
CA2650290A1 (en) 2007-11-08
IL194762A (en) 2014-09-30
WO2007127175A3 (en) 2007-12-27
EP2041139B1 (en) 2011-11-09
HK1127356A1 (en) 2009-09-25
IL194762A0 (en) 2009-08-03
AU2007243457A1 (en) 2007-11-08
TWI498332B (zh) 2015-09-01
CN101479274A (zh) 2009-07-08
KR20090014283A (ko) 2009-02-09
AU2007243457B2 (en) 2012-02-23
PT2041139E (pt) 2012-01-13
KR101422301B1 (ko) 2014-07-30
EP2402347A1 (en) 2012-01-04
JP2009538825A (ja) 2009-11-12
JP5546240B2 (ja) 2014-07-09
ZA200809546B (en) 2010-04-28
CN101479274B (zh) 2013-06-12
US20140309216A1 (en) 2014-10-16
US9943519B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
NO20084928L (no) Farmasoytiske sammensetninger
NO20084927L (no) Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem
MX2010010659A (es) Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
UA108863C2 (ru) Бензоксепиновые ингибиторы pi3 и их применение
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
WO2009036082A3 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2007103308A3 (en) Heterobicyclic pyrazole compounds and methods of use
PH12013501779B1 (en) Pyrrolopyridines as kinase inhibitors
AU2009312464A8 (en) Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
NO20092566L (no) Fosfoinositid 3-kinaseinhibitorforbmdelser og fremgangsmater for anvendelse
NO20092565L (no) Fosfoinositid 3-kinaseinhibitorforbmdelser og fremgangsmater for anvendelse
WO2007146824A3 (en) Quinoline compounds and methods of use
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
BR112013014914A2 (pt) composto, composição farmacêutica, método de tratar câncer em um paciente e uso
WO2006125101A3 (en) Raf inhibitor compounds and methods of use thereof
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
WO2010105008A3 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
NO20081595L (no) Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
WO2008063202A3 (en) Heterobicyclic thiophene compounds for the treatment of cancer
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application